©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Molecular Characterization of hasC from an Operon Required for Hyaluronic Acid Synthesis in Group A Streptococci
DEMONSTRATION OF UDP-GLUCOSE PYROPHOSPHORYLASE ACTIVITY (*)

(Received for publication, August 9, 1995; and in revised form, September 27, 1995)

Dinene L. Crater (§) Brian A. Dougherty (§) Ivo van de Rijn (¶)

From the Wake Forest University Medical Center, Winston-Salem, North Carolina 27157

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Hyaluronic acid is a high molecular weight glycosaminoglycan composed of repeating subunits of glucuronic acid and N-acetylglucosamine. It is synthesized by the group A streptococcal membrane-associated enzyme hyaluronate synthase. In previous reports, the locus required for expression of hyaluronic acid, the has operon, was identified and found to consist of two genes, hasA and hasB encoding hyaluronate synthase and UDP-glucose dehydrogenase, respectively. Since a transcription terminator was not found at the end of hasB, it was the aim of this study to identify the remaining gene(s) in the has operon. By utilizing the Tn1000 method of DNA sequencing and inverse polymerase chain reaction, hasC, the third gene in the has operon was shown to be 915 base pairs in length (304 amino acids) and located 192 base pairs downstream of hasB. Sequence similarities to other genes suggested that hasC encodes UDP-glucose pyrophosphorylase. Overexpression of hasC using isopropyl-1-thio-beta-D-galactopyranoside induction of the T7 promoter in the pET translation system allowed for the production of bacterial extracts from Escherichia coli that possessed increased UDP-glucose pyrophosphorylase activity as compared to nondetectable levels in extracts with vector alone. In addition, expression of HasC resulted in a protein of approximately 36 kDa as shown by SDS-polyacrylamide gel electrophoresis. These data as well as complementation analysis of hasC in an E. coli galU mutant confirmed that hasC encodes UDP-glucose pyrophosphorylase. Finally, since sequence analysis identified a potential rho-independent transcription terminator at the 3-prime terminus of the gene, hasC is the third and probably the final gene in the has operon.


INTRODUCTION

Group A streptococci (Streptococcus pyogenes) are human pathogens that colonize the skin and mucous membranes of their host. They cause localized infections and nonsupperative sequelae such as post-streptococcal glomerulonephritis and rheumatic fever(1) . Prior to 1985, the occurrence of lethal streptococcal infections was quite rare. However, a rise in the number of streptococcal diseases within the past decade has led to increased investigation into the mechanisms involved in the resurgence of disease. One potential explanation for this increased pathogenicity of group A streptococci could be that the bacteria have evolved enhanced virulence determinants that assist in the pathogenesis of the organism. The primary virulence factor for group A streptococci is the M protein. M protein is a coiled-coil dimeric molecule present on the surface of streptococci that has been shown to interfere with phagocytic uptake of the organism by neutrophils and protect the organism from clearance(2) . The hyaluronic acid capsule has also been shown to be involved in the pathogenicity of group A streptococci. It has been observed that clinical isolates from outbreaks of rheumatic fever are highly encapsulated as compared to nonpathogenic strains(3, 4) . Three percent of isolates from patients with uncomplicated pharyngitis (group I) possess a hyaluronate capsule, whereas 21% of isolates from severe streptococcal infections (group II), and 42% of rheumatic fever isolates (group III) exhibit a capsule. However, in the most frequently isolated group A streptococcal serotype, M1, the frequency of capsule production is even greater: 6% for group I, 22% for group II, and 80% for group III. These data support the hypothesis that the hyaluronic acid capsule is a major virulence determinant for group A streptococci in the human host.

To demonstrate that the hyaluronic acid capsule is necessary for pathogenesis of group A streptococci, Wessels et al.(5, 6) have created acapsular mutants via transposon mutagenesis that exhibited increased sensitivity to phagocytic killing in human blood, whereas the encapsulated wild-type strains survived killing. These same acapsular mutants were also less virulent in mice as compared to the wild-type streptococci. In addition, Wessels and Bronze (7) showed that the hyaluronate capsule is necessary for early colonization of the pharynx and may be required for invasion of group A streptococci from the pharynx to produce a disseminated infection. These results suggested that the hyaluronic acid capsule may provide a selective advantage over the unencapsulated phenotype for group A streptococci.

Hyaluronic acid is a high molecular weight glycosaminoglycan that is synthesized by the alternate addition of UDP-glucuronic acid and UDP-N-acetylglucosamine by the streptococcal membrane-associated enzyme hyaluronate synthase(8) . The chromosomal locus that is necessary for the production of the hyaluronic acid capsule (has operon) has recently been identified(9, 10, 11, 12, 13) and is conserved in all strains of group A streptococci and encapsulated group C streptococci(6, 14) . The has operon was found to consist of at least two genes, hasA and hasB. hasA was shown to encode hyaluronate synthase(11, 12, 13) . DeAngelis and Weigel (15) have created two monospecific antibodies raised against synthetic peptides corresponding to portions of HasA. Both antibodies recognized a 42-kDa protein from group A streptococci and a recombinant protein from Escherichia coli containing hasA on a plasmid. hasB was shown to encode UDP-glucose dehydrogenase(10) . Furthermore, a transposon insertion in hasA created a polar effect on hasB expression, providing evidence that the genes are transcribed by the same promoter. Since sequence analysis of DNA downstream of hasA did not reveal any terminator-like sequences(11) , the hasA promoter could regulate transcription of the entire operon and thereby produce a polycistronic message. Recently, it was demonstrated by Northern blot analyses that hasA, hasB, and hasC are located on the same mRNA transcript (4.2 kb), (^1)thus confirming the observation that the genes are components of an operon(14) .

In this report, the sequence of the third gene (hasC) of the has operon is presented. hasC is located 192 nucleotides downstream of hasB and contains a potential rho-independent terminator at the 3-prime end of the gene, thus suggesting that hasC is the last gene in the has operon. Sequence comparisons and T7 overexpression of hasC demonstrated that hasC encodes UDP-glucose pyrophosphorylase, an enzyme which catalyzes the production of UDP-glucose from glucose 1-phosphate and UTP.


EXPERIMENTAL PROCEDURES

Bacterial Strains and Plasmids

The streptococcal strain used in this study (WF51, T18) was grown in CDM(16) . E. coli strains used were JM109, BL21(DE3), DPWC, BW26(17) , and DEV6 (gift from the E. coli Genetic Stock Center, Yale University; lacZ105, , galU65, relA1, spoT1, thi-1) (18) grown in Luria broth or TYPG (16 g of tryptone, 16 g of yeast extract, 5 g of NaCl, 2.5 g of K(2)PO(4), and 5 g of glucose/liter of H(2)O; see (10) ) medium as indicated. Plasmids used in this study include pGAC144(10) , pGAC312 (this study), pGAC315 (this study), pMOB(17) , pBluescript (Stratagene), pET11a(19) , pLysE(19) , and pLysS(19) .

DNA Purification and Manipulations

Streptococcal chromosomal DNA was purified as per Dougherty and van de Rijn(9) . Plasmid DNA was purified from E. coli cultures (3 ml) by the alkaline lysis procedure (20) or Wizard Mini-Preps (Promega, Madison, WI) and resuspended in a final volume of 100 µl of TE (100 µl, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA). DNA restriction enzymes were purchased from Promega and used according to the manufacturer's suggestions.

Cloning and DNA Sequence of the hasC Gene

The 0.9-kb EcoRI/HindIII of pGAC144 was subcloned into the miniplasmid pMOB for sequencing utilizing the Tn1000 protocol as per Strathmann et al.(17) . Briefly, pMOB containing the 0.9-kb EcoRI/HindIII fragment was transformed into the host strain DPWC (which contains Tn1000 on the F factor) by the one-step method(20) . The F factor was then transferred to the recipient strain BW26 by conjugation and positive colonies were selected for on LB agar plates containing carbenicillin and kanamycin (100 µg/ml and 50 µg/ml, respectively). Twenty individual colonies were subjected to PCR to determine the position of insertion of the transposon within the target gene. Akaline lysis miniprep DNA (40 µl) was used as the template for double-stranded sequencing with Sequenase version 2.0 (U. S. Biochemical Corp., Cleveland, OH).

To sequence the remaining 3-prime fragment of hasC, chromosomal DNA from streptococcal strain WF51 was digested with XbaI and BglII and electrophoresed, and a 3-5.5-kb region was extracted from the gel and purified using beta-agarase (New England Biolabs, Beverly, MA). The ends of the isolated fragments were blunted and ligated, creating a cirular piece of DNA that spans from the BglII site in the 5-prime region of hasA (11) to the XbaI site downstream of hasC. The DNA was then subjected to inverse PCR using oligonucleotides D-10 (5`-CTTAGAACACCCACAGGTC-3`) and D-11 (5`-CATTTGGATAGATATAAGTATC-3`) as primers. The 1.4-kb PCR product was gel-purified by beta-agarase and subjected to double-stranded DNA sequencing using Sequenase version 2.0. This process starting with PCR was repeated three times with identical results obtained each time.

The complete sequence of hasC was determined by utilizing the fragment assembly program of the GCG software package(21) . BESTFIT and PILEUP, additional GCG programs, were used to align other sequences in the data base with hasC. FOLDRNA was used to determine the secondary structure of hasC.

Complementation of E. coli galU Mutation

pGAC315 or pET11a was transformed into the E. coli galU mutant strain DEV6 (18) , and single colonies were grown in chromogenic medium (3 ml; 1% polypeptone, 0.5% yeast extract, 2% galactose, 0.003% bromthymol blue, 0.5 mM IPTG, 50 µg/ml ampicillin) (22) at 37 °C. Complementation was judged successful by a color change of the culture supernatant from green to yellow that demonstrated the ability of the hasC-complemented mutant to produce acid from growth in galactose.

T7 Overexpression of hasC in E. coli

In order to express hasC, chromosomal DNA isolated from WF51 was subjected to PCR using oligonucleotide D-34a (5`-GCACATATGACCAAAGTCAGAAAAG-3`) to incorporate an NdeI site at the 5-prime end of hasC and oligonucleotide D-37a (5`-GCAGGATCCAAGTACCAACACATTACTTTG-3`) to incorporate a BamHI site at the 3-prime end for further subcloning into the translation vector pET11a. The 925-base pair PCR product was subjected to T4 polynucleotide kinase (Promega) in order to phosphorylate the ends and then subcloned into SmaI-digested pBluescript II (KS) to create pGAC312. Next, hasC was removed from pGAC312 by restriction digestion with NdeI and BamHI and finally subcloned into NdeI/BamHI-digested pET11a to create pGAC315.

pGAC315 was transformed into E. coli strains BL-21(DE3), BL-21(DE3)(pLysE), and BL-21(DE3)(pLysS) in order for T7 expression experiments. As a plasmid control, pET11a was also transformed into the above strains. T7 overexpression of hasC was achieved as per Studier et al.(19) . Briefly, TYPG (5 ml) was inoculated with a single microcolony from the above transformations, and grown at 37 °C until the optical density of the culture at 600 nm reached 0.6. At this point, 1 ml of the culture was removed as a preinduction sample, and IPTG (1 mM final concentration) was added to the remaining culture followed by a further incubation period. Additional 1-ml samples were taken at 2 and 3 h post-IPTG induction, and the samples were sedimented at 13,000 times g for 10 s and finally resuspended in TE. Sample buffer (60 µl) was added to each sample and boiled for 5 min to solubilize the cells. Thirty microliters of preinduction lysates and 10 µl of 2- and 3-h lysates were loaded per lane on a 10% SDS-PAGE gel and electrophoresed as per Laemmli (23) .

For overexpression of larger quantities of HasC for enzymatic assays, TYPG media (50 ml) was inoculated with 500 µl of an overnight culture of BL-21(DE3)(pLysS)(pGAC315) or BL-21(DE3)(pLysS)(pET11a) and grown to OD = 0.9. A preinduction sample (8.5 ml) was removed from the culture, IPTG (1 mM final concentration) was added to the remaining culture, and the incubation was resumed. Aliquots (8.5 ml) were removed from each of the cultures at 3 h postinduction. The samples were sedimented at 10,000 times g for 10 min, and the pellet was resuspended in enzyme buffer (1 ml, 50 mM potassium phosphate, pH 8.7) for subsequent enzyme assays.

Detection of hasC Enzyme Activity

Bacterial cells were disrupted by glass bead breakage as per Dougherty and van de Rijn(10) . Modifications of the procedure included the buffer used for prewashing the glass beads and resuspension of the bacterial cells (50 mM potassium phosphate, pH 8.7), and the cells were broken only two times in the minibead breaker. UDP-glucose pyrophosphorylase activity was monitored using the coupled reaction with the enzymes phosphoglucomutase and glucose-6-phosphate dehydrogenase as described by Joshi (24) and modified by Fjaervik et al.(25) . Potassium phosphate (50 mM, pH 8.7) was substituted for the reaction buffer since the imidazole-HCl buffer inhibited the streptococcal enzyme. The reaction was initiated upon addition of crude enzyme (10 µl) to a 1-ml cuvette containing assay buffer (750 µl, prewarmed to 30 °C). The subsequent reduction of NADP at 340 nm was monitored using a Spectronic 2000 (Bausch & Lomb), and the reaction rate was calculated from the initial linear portion of the curve (reduction of NADP versus time). Only trace amounts, if any, of reducing activity were found in the extracts in the absence of UDP-glucose, and the values were subtracted from the data. Protein concentration was determined by the Markwell et al.(26) assay using duplicate samples and BSA as standard. A unit of UDP-glucose pyrophosphorylase activity was defined as the amount of enzyme required to produce 1 µmol of NADPH/min at 30 °C.


RESULTS

Cloning and DNA Sequence of the hasC Gene

Further analysis of pGAC144, a clone that contained the 3-prime region of hasB and approximately 1 kb of additional DNA(10) , identified an open reading frame 192 nucleotides downstream of hasB. In order to sequence this open reading frame, the 0.9-kb EcoRI/HindIII fragment of pGAC144 (beginning 130 nucleotides downstream of hasB) was subcloned into the minivector pMOB and subjected to Tn1000 sequencing as per Strathmann et al.(17) . The open reading frame, designated hasC, was shown to initiate 62 nucleotides downstream of the EcoRI site (Fig. 1); however, the 3-prime end of the gene (up to the HindIII site) did not contain a stop codon. Additional experiments were initiated to determine the sequence of the remaining portion of hasC. Chromosomal DNA was isolated from WF51 (the prototype encapsulated strain of group A streptococci), cloned to form a circular piece of DNA, and subjected to inverse PCR using primers D-10 and D-11 (see ``Experimental Procedures''). The 1.4-kb PCR product was then sequenced using hasC primers to complete the sequence of hasC. A termination codon (TAA) was found 39 nucleotides (12 amino acids) downstream of the HindIII site of pGAC144, thus identifying the end of hasC.


Figure 1: Nucleotide sequence of hasC gene. The nucleotide sequence of hasC and the surrounding regions (including the 3-prime end of hasB) is presented and the predicted amino acid sequence is shown below the open reading frame. A potential ribosome binding site (AGTGAGGAG) is underlined and restriction sites are noted above the nucleotides. A potential rho-independent transcription terminator is shown in bold. The dashed arrows represent the PCR primers (D-34a and D-37a) that were used to synthesize hasC for T7 expression.



hasC was demonstrated to consist of 915 base pairs (304 amino acids, approximately 33.7 kDa) and possesses a potential Shine-Delgarno sequence (Fig. 1; RBS, base pairs 176-184) capable of base pairing with the 3-prime terminus of the streptococcal 16 s rRNA(27) . Weak -35 and -10 sites were observed upstream of the hasC start codon; however, primer extension analysis did not identify a transcription start site directly upstream of hasC (data not shown), and Northern analyses demonstrated that hasC was part of the 4.2-kb has operon transcript(14) . A potential transcriptional terminator was located within the 3-prime end of hasC spanning an additional 24 base pairs past the hasC termination codon. These data suggested that hasC is the third and last gene in the has operon.

Comparison of hasC to Other Bacterial UDP-glucose Pyrophosphorylases

Sequence comparisons using the FASTA program of the Genetics Computer Group software package (21) revealed that hasC shows homology to other genes that encode UDP-glucose pyrophosphorylase. HasC displayed 71.2% identity (initn, 1682) to Cps3U from type 3 Streptococcus pneumoniae(28) (Fig. 2), 63.5% identity (initn, 667) to GtaB from Bacillus subtilis(29) , 57.5% identity (initn, 432) to E. coli GalU(30) , 53.6% identity (initn, 218) to CelA of Acetobacter xylinum(31) , and 52.8% identity (initn, 178) to Rhizobium meliloti ExoN(32) . The lysine residue essential for catalytic activity of UDP-glucose pyrophosphorylase from potato tuber has previously been determined(33) . Alignment of the surrounding 9 amino acid residues with HasC and Cps3U demonstrated homology with 6 residues including the catalytic lysine (Fig. 2). Further experimentation is required to determine whether this lysine is involved in catalysis in the streptococcal enzyme.


Figure 2: Alignment of the HasC and Cps3U amino acid sequences. An optimal alignment of HasC and Cps3U proteins was generated using BESTFIT program from GCG software package. Bars represent identical amino acids; single dots, similarities of <0.5 but >1.0; and double dots, similarities that are >0.5 between the residues. The shaded region indicates the region of identity around the active site lysine with potato tuber enzyme. The bold lysine residue identifies the catalytic lysyl residue defined by Katsube et al.(33) .



Complementation of E. coli GalU Mutation

To confirm that hasC encodes UDP-glucose pyrophosphorylase, pGAC315 or pET11a were transformed into DEV6, an E. coli K-12 strain that has a mutation in galU and is therefore deficient in UDP-glucose pyrophosphorylase activity(18) . After growth in chromogenic medium containing bromthymol blue, the clone containing pGAC315 produced acid from galactose as exhibited by the color change from green to yellow. JM109 cells (galU) served as a positive control. However, the clone that contained the vector without hasC or untransformed DEV6 were unable to ferment galactose. These observations further indicated that hasC encodes UDP-glucose pyrophosphorylase.

Overexpression of hasC in E. coli

To determine the molecular size of its gene product, hasC was subcloned under the control of the T7 promoter in the pET11a translation vector (see ``Experimental Procedures''). For T7 expression, transformants harboring pGAC315 or pET11a were grown in TYPG and induced with 1 mM IPTG. Transformants containing pLysS and pGAC315 produced the maximum amount of overexpression as compared to transformants harboring pLysE or BL-21(DE3) alone (data not shown). Control cells harboring pET11a did not exhibit overexpression of new proteins (Fig. 3; pET11a, lanes 0, 2, and 3) as compared to cells containing pGAC315 (lanes 2 and 3) which demonstrated overexpression of a 36-kDa protein at 2 and 3 h postinduction with IPTG. This band was not enhanced in extracts of cells harboring pGAC315 prior to IPTG induction (Fig. 3, lane 0).


Figure 3: Analysis of bacterial lysates from T7 expression by SDS-PAGE. BL-21(DE3)(pLysS) cells containing either pGAC315 or pET11a vector alone were grown to an optical density at 600 nm of 0.6 and induced with 1 mM IPTG. Lane 0, bacteria removed prior to induction with IPTG. Lanes 2 and 3, samples removed 2 and 3 h postinduction, respectively. The size of the overexpressed HasC, 36 kDa, is indicated at the left.



Analysis of UDP-Glucose Pyrophosphorylase Activity

Following the expression of hasC in E. coli, cell extracts were assayed for UDP-glucose pyrophosphorylase activity as described under ``Experimental Procedures'' in order to confirm that hasC coded for UDP-glucose pyrophosphorylase. In these experiments, BL-21(DE3)(pLysS) harboring the pET11a expression plasmid did not demonstrate UDP-glucose pyrophosphorylase activity before or after induction. Similarly treated BL-21(DE3)(pLysS) harboring pGAC315 demonstrated UDP-glucose pyrophosphorylase activity only after IPTG induction (specific activity 0.13 unit/mg of protein). Substitution of UDP-galactose for UDP-glucose in the assays demonstrated no activity in uninduced or IPTG-induced organisms (data not shown).


DISCUSSION

Sequence and homology analyses demonstrated that hasC encoded UDP-glucose pyrophosphorylase, the enzyme that in the presence of UTP catalyzes the reaction of glucose 1-phosphate to UDP-glucose. UDP-glucose is the substrate for the gene product of hasB, UDP-glucose dehydrogenase, responsible for the production of UDP-glucuronic acid in the presence of NAD. Finally, UDP-glucuronic acid is a component of the hyaluronic acid capsule for group A streptococci which is synthesized by the membrane associated enzyme hyaluronate synthase encoded by hasA. All three genes have been shown to be components of the has operon(10, 11, 14) . It has previously been shown by Southern analysis that the three genes that comprise the operon are located on the same 8.4-kb XbaI restriction fragment. In addition, Northern blot analyses demonstrated that hasA, hasB, and hasC are contained within a 4.2-kb mRNA transcript. Sequence data revealed that hasC is located 192 nucleotides downstream of hasB. This is a substantial distance for sequential genes in an operon in streptococci where the distance between hasA and hasB is only 37 nucleotides. Potential transcription initiation sites were observed between hasB and hasC; however, primer extension analyses of the entire 192 nucleotide region using multiple primers did not reveal an initiation site (data not shown) providing further evidence that hasC is a constituent of the has operon. Since hasC is not transcribed from its own promoter, the distance between hasB and hasC may be important for structural requirements or interaction with proteins involved in translation machinery.

Our previous Northern analysis data (14) and the presence of a potential rho-independent terminator at the 3-prime end of hasC gene (Fig. 1, bold) provides strong evidence that hasC is the last gene comprising the has operon. Characteristics of a strong terminator include dyad symmetry, an inverted repeat containing 6-8 uracil residues, and a stem-loop rich in G and C nucleotides. The stem of the terminator for hasC is 25 nucleotides in length and contains 6 A-T pairs, the loop consists of 5 nucleotides (CAAAGT), and there are 16 G or C nucleotides (Fig. 4). Although the terminator of hasC complies with all of the requirements for a rho-independent terminator, further experimentation is required to confirm that this potential structure is the transcription termination site of the has operon.


Figure 4: Hypothetical structure of the rho-independent transcription terminator of the has operon. The RNA secondary structure of nucleotides 1072-1129 of hasC was created by using GCG software FOLDRNA program.



To overexpress hasC in E. coli, the pET-T7 expression system was utilized. This system employed the use of various plasmids to enhance the expression of the gene of interest, especially genes that may be toxic to the cell. For overexpression of hasC, transformants harboring pLysS were found to produce maximal amounts of HasC (Fig. 3), as compared to transformants containing pLysE or BL-21(DE3) alone (data not shown). The higher level of lysozyme produced from pLysE has been shown to interfere with the growth rate of the bacteria and may decrease the amount of transcription after IPTG induction. As with the previous expression of hasB (10) it was important to use low copy number plasmids under tight transcription control for expression of the gene product in E. coli.

The predicted size for HasC was approximately 33.7 kDa which is in good agreement with the product of the T7 overexperssion of hasC in E. coli (36 kDa). Variation in the predicted size from the size demonstrated by SDS-PAGE also was seen with other bacterial UDP-glucose pyrophosphorylases. GalU was shown to be 40 kDa (predicted size, 32.9 kDa) (22, 30) and CelA was 30 kDa (predicted size, 30.9 kDa) (31) . The size difference between the predicted and the actual size determined by SDS-PAGE could be due to secondary structure of the protein causing the protein to migrate through the gel slower than expected.

Also as with the expression analysis of group A streptococcal UDP-glucose dehydrogenase (HasB)(10) , induction of group A streptococcal UDP-glucose pyrophosphorylase in E. coli appears to have led to a greater expression of protein (Fig. 3) than enzyme activity. Analysis of crude extracts indicated that enzyme activity versus protein concentration appeared approximately linear (data not shown) and that no NADPH oxidation was demonstrated. One important consideration is that the enzyme is labile and/or inhibited by components of the assay system. Toward this hypothesis it was determined that both imidazole-HCl and Tricine-NaOH buffers greatly inhibited the streptococcal enzyme (data not shown). Both of these buffers have previously been used for other UDP-glucose pyrophosphorylase assays(24, 25) . Finally, the specific activity of various preparations of the streptococcal UDP-glucose pyrophosphorylase varied 2-4-fold when expressed in E. coli (data not shown). This did not appear to be due to granule formation since all of the enzyme activity could be retrieved from the cytoplasmic fraction.

UDP-glucose pyrophosphorylase is found in a wide variety of organisms (plant, animals, and bacteria) and provides UDP-glucose for the biosynthetic pathways of many carbohydrates (sucrose, cellulose, and glycogen) as well as hyaluronic acid. The most detailed work on UDP-glucose pyrophosphorylase has been done using the cDNA from potato tuber(34) . The cDNA has been cloned and the recombinant protein expressed in E. coli(33) . The active site of the enzyme was shown to include 5 key lysine residues, as shown by site-directed mutagenesis and affinity labeling(33) . Hossain et al.(22) have demonstrated that prokaryotic UDP-glucose pyrophosphorylases are structurally diverse from the eukaryotic enzyme. Although HasC and other prokaryotic UDP-glucose pyrophosphorylases do not possess sequence homology with the potato tuber enzyme or other eukaryotic pyrophosphorylases, many contain the lysine residue found to be indespensible for enzyme function (Fig. 2, Lys-367 from potato tuber). However, further structural analysis of the catalytic sites of these enzymes are required in order to confirm whether this lysine is necessary for enzymatic activity in the prokaryote UDP-glucose pyrophosphorylases.

In summary, our previous Northern analysis data demonstrating a single 4.2-kb transcript (14) and the observed putative rho-independent terminator at the 3-prime end of hasC would indicate that the has operon is composed of hasA, hasB, and hasC. On going experiments include analysis of regulatory factors that may assist in the control of has operon transcription during exponential phase of growth. Finally, purification of the expressed HasC protein will be required to determine its enzyme kinetics and an analysis of its active site is required for comparison to other prokaryote and plant and animal UDP-glucose pyrophosphorylases to better understand the evolutionary differences between these enzymes.


FOOTNOTES

*
This work was supported in part by United States Public Health Service, National Institutes of Health Grant AI37320 (to I. v. d. R.), North Carolina Heart Association Grant-in-Aid NC-94-SA-09 (to D. L. C.), and the Oligonucleotide Core Laboratory of the Comprehensive Cancer Center of Wake Forest University (CA12107). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank(TM)/EMBL Data Bank with accession number(s) U33452[GenBank].

§
Predoctoral trainee (T32-AI-07401) of the National Institutes of Health.

To whom correspondence should be addressed: Wake Forest University Medical Center, Medical Center Blvd., Winston-Salem, NC 27157. Tel.: 910-716-2263; Fax: 910-716-4204.

(^1)
The abbreviations used are: kb, kilobase; IPTG, isopropyl-1-thio-beta-D-galactopyranoside; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis.


ACKNOWLEDGEMENTS

We are indebted to I. Blomfield who assisted with the pET-T7 expression system and R. Paul Ross and D. Ward who provided aid with Tn1000 sequencing.


REFERENCES

  1. Veasy, L. G., Wiedmeier, S. E., Orsmond, G. S., Ruttenberg, H. D., Boucek, M. M., Roth, S. J., Tait, V. F., and Thompson, J. A. (1987) N. Engl. J. Med. 316, 421-427 [Abstract]
  2. Lancefield, R. C. (1962) J. Immunol. 89, 307-313 [Medline] [Order article via Infotrieve]
  3. Johnson, D. R., Stevens, D. L., and Kaplan, E. L. (1992) J Infect. Dis. 166, 374-382 [Medline] [Order article via Infotrieve]
  4. Pancholi, V., and Fischetti, V. A. (1992) J Exp. Med. 176, 415-426 [Abstract]
  5. Wessels, M. R., Moses, A. E., Goldberg, J. B., and DiCesare, T. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8317-8321 [Abstract]
  6. Wessels, M. R., Goldberg, J. B., Moses, A. E., and DiCesare, T. J. (1994) Infect. Immun. 62, 433-441 [Abstract]
  7. Wessels, M. R., and Bronze, M. S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12238-12242 [Abstract/Free Full Text]
  8. Markovitz, A., Cifonelli, J. A., and Dorfman, A. (1959) J. Biol. Chem. 234, 2343-2350 [Free Full Text]
  9. Dougherty, B. A., and van de Rijn, I. (1992) J. Exp. Med. 175, 1291-1299 [Abstract]
  10. Dougherty, B. A., and van de Rijn, I. (1993) J Biol. Chem. 268, 7118-7124 [Abstract/Free Full Text]
  11. Dougherty, B. A., and van de Rijn, I. (1994) J. Biol. Chem. 269, 169-175 [Abstract/Free Full Text]
  12. DeAngelis, P. L., Papaconstantinou, J., and Weigel, P. H. (1993) J. Biol. Chem. 268, 14568-14571 [Abstract/Free Full Text]
  13. DeAngelis, P. L., Papaconstantinou, J., and Weigel, P. H. (1993) J. Biol. Chem. 268, 19181-19184 [Abstract/Free Full Text]
  14. Crater, D. L., and van de Rijn, I. (1995) J. Biol. Chem. 270, 18452-18458 [Abstract/Free Full Text]
  15. DeAngelis, P. L., and Weigel, P. H. (1994) Biochemistry 33, 9033-9039 [Medline] [Order article via Infotrieve]
  16. van de Rijn, I., and Kessler, R. E. (1980) Infect. Immun. 27, 444-448 [Medline] [Order article via Infotrieve]
  17. Strathmann, M., Hamilton, B. A., Mayeda, C. A., Simon, M. I., and Meyerowitz, E. M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1247-1250 [Abstract]
  18. Remes, B. and Elseviers, D. (1980) J. Bacteriol. 143, 1054-1056 [Medline] [Order article via Infotrieve]
  19. Studier, F. W., Rosenberg, A. H., Dunn, J. J., and Dubendorff, J. W. (1990) Methods Enzymol. 185, 60-89 [Medline] [Order article via Infotrieve]
  20. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1987) Current Protocols in Molecular Biology , Wiley, New York
  21. Devereux, J., Haeberli, P., and Smithies, O. (1984) Nucleic Acids Res. 12, 387-395 [Abstract]
  22. Hossain, S. A., Tanizawa, K., Kazuta, Y., and Fukui, T. (1994) J. Biochem. (Tokyo) 115, 965-972 [Abstract]
  23. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  24. Joshi, J. G. (1982) Methods Enzymol. 89, 599-605 [Medline] [Order article via Infotrieve]
  25. Fjaervik, E., Frydenlund, K., Valla, S., Huggirat, Y., and Benziman, M. (1991) FEMS Microbiol. Lett. 77, 325-330
  26. Markwell, M. A. K., Haas, S. M., Bieber, L. L., and Tolbert, N. E. (1978) Anal. Biochem. 87, 206-210 [Medline] [Order article via Infotrieve]
  27. Ludwig, W., Seewaldt, E., Kilpper-Balz, R., Schleifer, K. H., Magrum, L., Woese, C. R., Fox, G. E., and Stackebrandt, E. (1985) J. Gen. Microbiol. 131, 543-551 [Medline] [Order article via Infotrieve]
  28. Dillard, J. P., Vandersea, M. W., and Yother, J. (1995) J. Exp. Med. 181, 973-983 [Abstract]
  29. Varon, D., Boylan, S. A., Okamoto, K., and Price, C. W. (1993) J. Bacteriol. 175, 3964-3971 [Abstract]
  30. Weissborn, A. C., Liu, Q., Rumley, M. K., and Kennedy, E. P. (1994) J. Bacteriol. 176, 2611-2618 [Abstract]
  31. Brede, G., Fjaervik, E., and Valla, S. (1991) J. Bacteriol. 173, 7042-7045 [Medline] [Order article via Infotrieve]
  32. Glucksmann, M. A., Reuber, T. L., and Walker, G. C. (1993) J. Bacteriol. 175, 7045-7055 [Abstract]
  33. Katsube, T., Kazuta, Y., Tanizawa, K., and Fukui, T. (1991) Biochemistry 30, 8546-8551 [Medline] [Order article via Infotrieve]
  34. Nakano, K., Omura, Y., Tagaya, M., and Fukui, T. (1989) J. Biochem. (Tokyo) 106, 528-532 [Abstract]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.